

i-SIGHT2 CLINICAL STUDY FOR DRY AMD

i-LUMEN—FOUNDED IN OPTOMETRY

i-Lumen Scientific is a U.S. based “bioelectric” medical device manufacturer using non-invasive neurostimulation as an ophthalmic therapeutic. i-Lumen’s focus is the improvement of visual function in patients with vision loss due to Intermediate to Advanced nonexudative (dry) AMD.

i-Lumen’s Founder, U.S. Optometrist John Jarding, had a growing population of patients with AMD and no treatment options for them. That unmet need started him down a path that led to the identification of microcurrent stimulation as a potential therapy to activate the retinal cells, and the development of the i-Lumen AMD therapy.


The i-Lumen AMD therapy is an in-office, transpalpebral, microcurrent therapy that uses a proprietary combination of waveforms and frequencies to support multiple cell-types within the retinal layers.

i-SIGHT2 STUDY

i-SIGHT2 is a randomised, sham-controlled study to evaluate the i-Lumen AMD therapy in patients with Intermediate to Advanced dry AMD. Participants meeting eligibility will complete an initial 5-day treatment regimen and return for monthly visits for 14 Months, which will include 7 additional single days of maintenance treatments.

Key Eligibility Criteria for the i-SIGHT2 Study:

- 60 years of age or older
- Intermediate to Advanced dry AMD in one/both eyes
- Presence of at least 1 large drusen
- Visual Acuity 6/12 to 6/60
- No exudative (wet) AMD in both eyes
- No significant retinal or corneal disease
- No diabetic retinopathy
- No visually significant cataracts or posterior capsular opacification that may require a procedure within the next 12 months
- No diagnosis of severe dry eye disease requiring artificial tears more than 6x day or prescription drops
- No glaucoma requiring ≥ 3 medications and/or drops per day
- No high myopia or former high myopia ≥ 6 dioptres
- No history of amblyopia
- No implanted electrical devices
- Non-smoker or no history of heavy smoking in last 5 years



Site Name Goes Here

CONTACT [NAME] AT: **00 000 0000**

EMAIL: **research@address**